

**Consolidated Financial Results for the Fiscal Year
Ended 31 December 2014(Japanese GAAP)**

February 13, 2015

Company name UMN Pharma Inc. Stock Listings Mothers of the TSE
 Securities code 4585 URL <http://www.umnpharma.com/en/>
 Representative Hirano Tatsuyoshi Chairman and CEO
 Contact person Hiroyuki Hashimoto CFO (TEL)+81-45-263-9200
 Scheduled date of ordinary general shareholders' meeting March 27, 2015 Scheduled date of Dividend payments —
 Scheduled date of filing securities report March 30, 2015
 Supplementary materials for financial results : None
 Briefing session of financial results : Yes (For institutional investors and analysts(in Japanese only))

(Rounded down to nearest million yen)

1. Consolidated Financial Results for Fiscal Year Ended Dec. 31, 2014 (From Jan. 1, 2014 to Dec. 31, 2014)

(1) Consolidated operating results (Percentage indicate changes from the previous term)

	Net sales		Operating income		Ordinary income		Net income	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
FY2014	1,108	—	(3,942)	—	(4,249)	—	(3,961)	—
FY2013	93	(13.7)	(4,421)	—	(4,147)	—	(3,717)	—

(Note) Comprehensive income FY2014 (4,006) Million yen (—%) FY2013 (4,227) Million yen (—%)

	Net income per share - basic	Net income per share - diluted	Net income as percentage of net assets	Ordinary income as percentage of total assets	Operating income as percentage of net sales
	Yen	Yen	%	%	%
FY2014	(452 34)	—	(100.2)	(26.7)	(355.7)
FY2013	(491 59)	—	(87.3)	(25.1)	(4,735.5)

(Note) Equity in net income of affiliates FY2014 — Million yen FY2013 — Million yen

(2) Consolidated financial position

	Total assets	Net assets	Net assets as percentage of total assets	Net assets as percentage of net sales per share
	Million yen	Million yen	%	Yen
FY2014	12,882	3,705	28.8	387 74
FY2013	19,001	4,253	22.1	498 74

(Note) Shareholders' equity FY2014 3,705 Million yen FY2013 4,202 Million yen

(3) Consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of fiscal year
	Million yen	Million yen	Million yen	Million yen
FY2014	314	(8)	(2,493)	2,080
FY2013	(3,578)	(4,150)	8,113	4,267

2. Dividends

	Annual dividends per share					Total dividends	Payout ratio(consolidated)	Dividends as percentage of net assets(consolidated)
	End of Q1	End of Q2	End of Q3	Year end	Total			
	Yen	Yen	Yen	Yen	Yen	Million yen	%	%
FY2013	—	0 00	—	0 00	0 00	—	—	—
FY2014	—	0 00	—	0 00	0 00	—	—	—
FY2015(forecast)	—	0 00	—	0 00	0 00		—	

3. Forecast for Fiscal Year ending Dec. 31, 2015(from Jan. 1, 2015 to Dec. 31, 2015)

(Percentage indications show changes from corresponding figures for the previous period)

	Net sales		Operating income		Ordinary income		Net income		Net income per share
	Million yen	%	Million yen	%	Million	%	Million yen	%	Yen
FY2015	5,224	371.3	(878)	—	(1,025)	—	(1,033)	—	(108 14)

* Notes

(1) Changes in the number of significant subsidiaries during the fiscal year(changes of specified subsidiaries affecting the scope of consolidation) : None

(2) Changes in accounting policies, changes in accounting estimates, and restatements

- 1) Changes due to revised accounting standards : None
 2) Changes due to revised accounting policies except 1) : None
 3) Changes in accounting estimates : None
 4) Restatements : None

(3) Number of common shares issued

1) number of shares issued at fiscal year end (including treasury shares)

FY2014	9,556,500	FY2013	8,425,900
--------	-----------	--------	-----------

2) Number of treasury shares at fiscal year end

FY2014	50	FY2013	50
--------	----	--------	----

3) Average number of shares issued during fiscal year

FY2014	8,757,251	FY2013	7,561,412
--------	-----------	--------	-----------

(Reference) Summary of Non-consolidated Financial results

1. Non-consolidated Financial Results for Fiscal Year Ended Dec. 31, 2014(from Jan. 1, 2014 to Dec.31, 2014)

(1) Non-consolidated operating results (Percent indications show percent changes from corresponding figures for the Previous period)

	Net sales		Operating income		Ordinary income		Net income	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
FY2014	1,108	—	(2,861)	—	(2,820)	—	(2,822)	—
FY2013	92	(14.1)	(3,301)	—	(3,179)	—	(3,207)	—

	Net income per share – basic	Net income per share – diluted
	Yen	Yen
FY2014	(322 29)	—
FY2013	(424 14)	—

(2) Non-consolidated financial position

	Total assets	Net assets	Net assets as percentage of total assets	Net assets per share
	Million yen	Million yen	%	Yen
FY2014	7,031	6,307	89.7	660 01
FY2013	7,493	5,671	75.6	672 38

(Note) Shareholders' equity FY2014 6,307 Million yen FY2013 5,665 Million yen

* Disclosure concerning the implementation status of audit procedures

This financial report is exempt from audit procedures as stipulated under the Financial Instruments and Exchange Act of Japan. At the date of disclosure, financial statement audit procedures have not been completed as stipulated under the Financial Instruments and Exchange Act of Japan.

** Explanation concerning the appropriate use of forecasts and other special instructions

(Notice regarding forward-looking statements)

1. Results forecasts and other forward-looking statements contained in these supplemental materials are based on a number of assumptions, beliefs and uncertainties in light of information available to management as of the publication date of these materials. In this regard, the Company does not promise to achieve forecasted results. Actual financial results may differ materially from what is forecasted depending on a number of important factors. Please refer to 1. Analysis of Operating Results and Financial Position (1) Analysis of operating results(Earning forecast for the fiscal year ending Dec. 31, 2015).

2. The Company currently plans to hold a conference for investors and analysts on February 16, 2015. The Presentation materials of the conference will be made available on the company's web pages as soon as possible after conference.

Contents of Attached Materials

1. Analysis of Operating Results and Financial Position.....	5
(1) Analysis of Operating Results	5
(2) Analysis of Financial Position	6
(3) Basic Policy on Distribution of Profits and Dividends for Current and Next Fiscal Year	7
2. Consolidated Financial Statements	8
(1) Consolidated Balance Sheets	8
(2) Consolidated Statements of Income and Comprehensive Income	10
(3) Consolidated Statements of Changes in Net Assets	12
(4) Consolidated Statements of Cash Flows	13

1. Analysis of Operating Results and Financial Position

(1) Analysis of Operating Results

(Current term operating results)

During this consolidated fiscal year, the operational resources of UMN Pharma Inc. (“the Company”) were focused on R&D activities of UMN-0502 (recombinant influenza HA vaccine for the prevention of seasonal influenza, hereinafter referred to as “UMN-0502”) and UMN-0501 (recombinant influenza HA vaccine (H5N1) for the prevention of pandemic influenza, hereinafter referred to as “UMN-0501”) in collaboration with Astellas Pharma Inc. (“Astellas”); and UMN-0901 (recombinant influenza HA vaccine (H9N2), hereinafter referred to as “UMN-0901”) for which the possibility of pandemic has been indicated by WHO besides H5N1; and UMN-2003 (recombinant norovirus VLP + recombinant rotavirus VP 6 combination vaccine, hereinafter referred to as “UMN-2003” for the prevention of norovirus and rotavirus that are principal causative virus of viral gastroenteritis); and UMN-2002 for the prevention of norovirus (recombinant norovirus VLP single vaccine, hereinafter referred to as “UMN-2002”). As to the above pipelines, the Company carried out development of UMN-0502 and UMN-0501 for Japan in collaboration with Astellas, and of UMN-0502, UMN-0501 and UMN-0901 for South Korea in collaboration with Ildong Pharmaceutical Co., Ltd.

For UMN-0502, the Company successfully achieved primary endpoints in the phase III clinical trial that was implemented in Japan by Astellas, and an application for marketing approval of recombinant influenza HA vaccine ASP7374 for the prevention of influenza was submitted to the Ministry of Health, Labour and Welfare in May, 2014 by Astellas. After such submission, the Company received milestone payments from Astellas.

Although the Company tried to reach an collaborative agreement for the Chinese market, after several negotiations with a number of Chinese entities, the Company determined that it is necessary to further evaluate the feasibility of such project as it identified some regulations imposed by the local government. On the other hand, the Company achieved a basic agreement between Protein Sciences Corporation (“PSC”) and IHI on evaluation of the feasibility of supplying drug substances of Flublok® (i.e. recombinant influenza HA vaccine for the prevention of seasonal influenza, which was approved by Food and Drug Administration in January 2013 and is being sold within U.S. market) manufactured at Gifu plant to PSC, utilizing unused capacity at Gifu plant which is operated by UNIGEN Inc., a consolidated subsidiary of UMN Pharma Inc..

At Gifu plant, the Process Validation for acquiring data for GMP compliance inspection was completed during the fiscal year. In November 5, 2014, the Company was granted a manufacturer’s license, which is required for manufacturing medicine pursuant to the prior Pharmaceutical Law (currently called as *Law for Ensuring the Quality, Efficacy, and Safety of Drugs and Medical Devices*, the Law No., 145 effective as of August 10, 1960, as amended by the Law No., 122 effective as of November 27, 2014). In addition, the Company received subsidies in amount of 2,213 million yen from the Ministry of Economy, Trade and Industry in February 2014.

As for UMN-2002, the Company reached a joint research agreement with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) in February 2014, under which the Company continued to carry out the research to verify the possibility of UMN-2002 development, using Daiichi Sankyo’s devices for new administration.

Regarding biopharmaceutical contract manufacturing business, the Company manufactured and delivered prospective antigens for new vaccines to the Infectious Disease Surveillance Center. The number of orders for the business is increasing steadily.

For financial respects, in March, 2014, UNIGEN repaid 4,845 million yen of syndicate loans, reducing the balance of syndicated loan to 6,490 million yen. In order to secure working capital for expected commercial production of UMN-0502 for the period ending December 2015 and thereafter, UNIGEN and Sumitomo Mitsui Banking Corporation agreed on extension of the commitment line facilities in the amount of 1,500 million yen from December 30, 2014 to June 30, 2015.

As a result, consolidated net sales for FY2014 totaled 1,108 million yen (increase of 1,087.1% compared to the corresponding period in the prior year) with operating loss of 3,942 million yen (4,421 million yen for the prior year), ordinary loss of 4,249 million yen (4,147 million yen for the prior year) and net loss of 3,961 million yen (3,717 million yen for the prior year).

(Earnings forecasts for the fiscal year ending Dec. 31, 2015)

The Company will allocate its operating resources mainly to activities for obtaining marketing approval for UMN-0502, an application for which was submitted by Astellas. Upon granting of such approval for UMN-0502 and after the product distribution is successfully commenced, the Company will receive a certain amount of milestone payments pursuant to the agreement with Astellas of September 2010, and thus realize revenue from sales of UMN-0502 product.

In South Korea, investigational drug for the phase III clinical trial to be carried out by Ildong will be supplied from Gifu plant, while in U.S., the Company will facilitate activities for exporting drug substances under the brand of Flublok® in collaboration with PSC and IHI to realize our growth scenario in the future and undertake efforts to procure a formal agreement on exporting drug substances to the U.S..

For UMN-2002, by advancing the joint research with Daiichi Sankyo, the Company is expected to receive some amount of proceeds based on the research contract. For UMN-2003, the Company will actively search for R&D partners to procure revenues from execution of the joint R&D contracts.

As for biopharmaceutical contract manufacturing business, the Company is expecting orders for new prospective biopharmaceuticals leveraging Baculovirus Expression Vector System (hereinafter referred to as “BEVS”), a next-generation recombinant technology platform for manufacturing biopharmaceutical products.

The Company will engage in absolute cost-control activities in order to further reduce expenses. However, some R&D expenses are projected as the Company will continue to collect necessary data to obtain approval for marketing of UMN-0502 and conduct R&D activities for better production efficiency. Other costs, regarding actively recruiting competent personnel to enhance our organization toward commercial production and borrowing short-term loan for working capital for the commercial production, are also expected.

As a result, the Company forecast, for the fiscal year 2015, net sales of 5,224 million yen, operating loss of 878 million yen, ordinary loss 1,025 million yen, and net loss of 1,033 million yen.

These forecasts are based on currently available information and assumptions that the Company we regard as reasonable. Actual financial results may substantially differ from these forecasts for various reasons.

(2) Analysis of Financial Position

The financial position as of the current consolidated fiscal year end is as follows.

Total assets as of the end of the current consolidated fiscal year amounted to 12,882 million yen, which corresponds to a decrease of 6,119 million yen compared to the prior year, mainly due to a decrease of fixed assets as a result of reduction entry.

Liabilities amounted to 9,176 million yen which corresponds to a decrease of 5,571million yen compared to the prior year, mainly due to repayment of the short-term and long-term loans.

Total assets amounted to 3,705 million yen which corresponds to a decrease of 548 million yen compared to the prior year. This is mainly because the Company recorded net loss of 3,961million yen although shareholders' equity and capital surplus increased by 1,732 million yen and 1,732 million yen, respectively, by way of both public stock offering and exercise of stock option.

Cash and cash equivalents position

The year-end balance of cash and cash equivalents decreased by 2,187 million yen to 2,080 million yen.

(Cash flows from operating activities)

Cash flows from operating activities amounted to 314 million yen, composed of loss before income taxes of 4,002 million yen, depreciation of 1,873 million yen, and subsidies received of 2,316 million yen.

(Cash flows from investing activities)

Cash flows from investing activities amounted to 8 million yen, composed of acquisition of tangible fixed assets in the amount of 5 million yen and acquisition of intangible fixed assets in the amount of 3 million yen.

(Cash flows from financing activities)

Cash flows from financing activities amounted to 2,493 million yen, composed of proceeds from the short-term loans of 2,470 million yen, repayment of the short-term loans of 3,384 million yen, repayment of the long-term loans of 4,920 million yen, and proceeds of issuance of common stock of 3,441 million yen.

Reference: movements of cash-flow-related indicators

	FY2010	FY2011	FY2012	FY2013	FY2014
Net assets as percentage of total assets	35.9	63.2	30.8	22.1	28.8
Based on current market capitalization of net assets as percentage of total assets	—	—	82.2	135.2	216.7
Cash flow-to-interest-bearing liabilities ratio	0.2	—	—	—	23.1
Interest coverage ratio	3,056.8	—	—	—	1.9

Net assets as percentage of total assets: Net assets / Total assets

Based on market current market capitalization of net assets as percentage of total assets: Current market capitalization / Total assets

Cash flow-to-interest-bearing liabilities ratio: Debt / Cash flows from operating activities

Interest coverage ratio: Cash flows from operating activities / Interest expense

(3) Basic Policy on Distribution of Profits and Dividends for Current and Next Fiscal Year

The Company recognizes that redistribution of profits to our shareholders is the most important issue in respect of our operation. However, it is necessary for it to upgrade existing pipelines and develop new pipeline, invest in production facilities, and enhance internal reserves for the mid and long-term growth. Thus, the Company will determine how to make redistribution of profits, in a comprehensive way, taking into consideration of operating performance, financial standing and business plan.

The Company determined that it will declare no dividend for the current fiscal year, based on our performance on a single and consolidated basis.

In respect of upcoming dividends, the Company also determined that it will declare no dividend at the 2nd quarter and the end of the fiscal year, as the Company recorded negative earned surplus.

2. Consolidated Financial Statements

(1) Consolidated Balance Sheets

(Thousands of yen)

	FY2013 (Dec. 31, 2013)	FY2014 (Dec. 31, 2014)
Assets		
Current assets		
Cash and cash equivalent	4,267,657	2,080,221
Accounts receivable	—	14,502
Work-in-process	514	338,602
Raw materials and supplies	106,081	348,261
Advances payments	72,871	88,712
Prepaid expenses	55,301	70,332
Consumption taxes receivable	789,050	150,428
Other	104,907	105,985
Total current assets	5,396,385	3,197,044
Noncurrent assets		
Tangible fixed assets		
Buildings and structures	6,392,443	5,954,737
Accumulated depreciation	(337,845)	(833,754)
Buildings and structures, net	6,054,598	5,120,982
Machinery and equipment	6,881,720	5,465,422
Accumulated depreciation	(913,196)	(2,054,744)
Machinery and equipment, net	5,968,524	3,410,677
Tools, furniture and fixtures	353,086	337,729
Accumulated depreciation	(180,407)	(232,946)
Tools, furniture and fixtures, net	172,679	104,783
Lease assets	734,625	744,359
Accumulated depreciation	(104,693)	(211,004)
Lease assets, net	629,932	533,355
Construction in progress	1,050	1,050
Total tangible fixed assets	12,826,784	9,170,849
Intangible fixed assets		
Software	410,984	245,362
Other	395	340
Total intangible assets	411,379	245,703
Investments and other assets		
Long-term prepaid expenses	360	1,160
Rental and guarantee deposits	66,884	67,293
Long-term account receivable	300,000	200,000
Total investments and other assets	367,244	268,453
Total noncurrent assets	13,605,408	9,685,006
Total assets	19,001,793	12,882,050

(Thousands of yen)

	FY2013 (Dec. 31, 2013)	FY2014 (Dec. 31, 2014)
Liabilities		
Current liabilities		
Short-term loan payable	1,484,300	600,000
Current portion of long-term loan payable	2,710,000	336,000
Lease obligations	94,071	100,538
Accounts payable	382,348	607,462
Income taxes payable	29,631	30,567
Advances received	11,200	—
Deposit received	8,537	18,779
Other	7,983	105,362
Total current liabilities	4,728,073	1,798,710
Noncurrent liabilities		
Long-term loan payable	8,875,000	6,329,000
Lease obligations	549,093	457,869
Long-term deposit received	340,332	340,332
Deferred tax liabilities	56,334	53,741
Asset retirement obligations	168,099	171,248
Other	31,368	25,739
Total noncurrent liabilities	10,020,229	7,377,931
Total liabilities	14,748,302	9,176,642
Net assets		
Shareholders' equity		
Capital stock	6,956,361	8,688,544
Capital surplus	6,625,361	8,357,544
Retained earnings	(9,379,249)	(13,340,482)
Treasury stock	(197)	(197)
Total shareholders' equity	4,202,277	3,705,408
Subscription right to shares	6,251	—
Minority interests	44,962	—
Total net assets	4,253,491	3,705,408
Total liabilities and net assets	19,001,793	12,882,050

(2) Consolidated Statements of Income and Comprehensive Income

Consolidated statements of income and loss

	(Thousands of yen)	
	FY2013 (From Jan. 1, 2013 to Dec. 31, 2013)	FY2014 (From Jan. 1, 2014 to Dec. 31, 2014)
Net sales	93,379	1,108,522
Cost of sales	27,232	173,971
Gross profit	66,146	934,551
Selling, general and administrative expenses	4,488,124	4,877,245
Operating loss (-)	(4,421,977)	(3,942,694)
Non-operating income		
Interest income	1,013	468
Gain on sales of securities	31,586	—
Income from grants	607,264	3,250
Other	2,141	588
Total not-operating income	642,006	4,306
Non-operating expenses		
Interest expenses	225,584	168,304
Stock issuance cost	18,504	22,705
Foreign exchange loss	2,581	5,917
Commission paid	121,256	114,480
Other	62	0
Total non-operation expenses	367,989	311,407
Ordinary loss (-)	(4,147,960)	(4,249,795)
Extraordinary income		
Gain on sales of stocks of subsidiary	7,473	—
Income from grant	—	2,213,799
Total extraordinary income	7,473	2,213,799
Extraordinary loss		
Advanced depreciation deduction	—	1,966,398
Total extraordinary loss	—	1,966,398
Loss before income tax and minority interests (-)	(4,140,486)	(4,002,394)
Income taxes	30,084	6,395
Income taxes-adjustment	51,763	(2,593)
Total income taxes	81,847	3,801
Net loss before minority interest (-)	(4,222,334)	(4,006,195)
Loss attributable to minority interests (-)	(505,216)	(44,962)
Net loss (-)	(3,717,117)	(3,961,233)

Consolidated statements of comprehensive income

	(Thousands of yen)	
	FY2013 (From Jan. 1, 2013 to Dec. 31, 2013)	FY2014 (From Jan. 1, 2014 to Dec. 31, 2014)
Loss before minority interest (-)	(4,222,334)	(4,006,195)
Other comprehensive income (loss)		
Net unrealized gains(losses) on available-for-sale securities	(5,075)	—
Total other comprehensive income (losses)	(5,075)	—
Comprehensive income (losses)	(4,227,410)	(4,006,195)
(Breakdown)		
Comprehensive income(losses) attributable to owners of the parent company	(3,722,193)	(3,961,233)
Comprehensive income(losses) attributable to minority interests	(505,216)	(44,962)

(3) Consolidated Statement of Changes in Net Assets

FY2013 (from Jan. 1, 2013 to Dec. 31, 2013)

(Thousands of yen)

	Shareholders' equity					Accumulated other comprehensive income(loss)		Subscription right to shares	Minority interest	Total net assets
	Common stock	Capital surplus	Retained earnings	Treasury stock	Total Shareholders' equity	Net unrealized gains(losses) on available for sale securities	Total accumulated other comprehensive income(loss)			
Balance at beginning of fiscal year	5,152,348	4,821,348	(5,662,131)	—	4,311,564	5,075	5,075	—	52,652	4,369,293
Changes during fiscal year										
Issuance of new shares	1,804,013	1,804,013			3,608,027					3,608,027
Net income(loss)			(3,717,117)		(3,717,117)					(3,717,117)
Purchase of treasury stock				(197)	(197)					(197)
Net changes of items other than shareholders' equity						(5,075)	(5,075)	6,251	(7,690)	(6,514)
Total changes during the period	1,804,013	1,804,013	(3,717,117)	(197)	(109,287)	(5,075)	(5,075)	6,251	(7,690)	(115,802)
Balance at end of the fiscal year	6,956,361	6,625,361	(9,379,249)	(197)	4,202,277	—	—	6,251	44,962	4,253,491

FY2014 (from Jan. 1, 2014 to Dec. 31, 2014)

(Thousands of yen)

	Shareholders' equity					Accumulated other comprehensive income(loss)		Subscription right to shares	Minority interest	Total net assets
	Common stock	Capital surplus	Retained earnings	Treasury stock	Total Shareholders' equity	Net unrealized gains(losses) on available for sale securities	Total accumulated other comprehensive income(loss)			
Balance at beginning of fiscal year	6,956,361	6,625,361	(9,379,249)	(197)	4,202,277	—	—	6,251	44,962	4,253,491
Changes during fiscal year										
Issuance of new shares	1,732,182	1,732,182			3,464,365					3,464,365
Net income(loss)			(3,961,233)		(3,961,233)					(3,961,233)
Net changes of items other than shareholders' equity								(6,251)	(44,962)	(51,213)
Total changes during the period	1,732,182	1,732,182	(3,961,233)		(496,868)			(6,251)	(44,962)	(548,082)
Balance at end of the fiscal year	8,688,544	8,357,544	(13,340,482)	(197)	3,705,408	—	—	—	—	3,705,408

(4) Consolidated Statements of Cash Flows

(Thousands of yen)

	FY2013 (From Jan. 1, 2013 to Dec. 31, 2013)	FY2014 (From Jan. 1, 2014 to Dec. 31, 2014)
Net cash provided by (used in) operating activities		
Net loss before income taxes and minority interests (-)	(4,140,486)	(4,002,394)
Depreciation	1,404,400	1,873,257
Interest income and dividends income	(1,013)	(468)
Loss(Profit) on sales of securities	(31,586)	—
Interest expenses	225,584	168,304
Commission paid	121,256	114,480
Stock issuance cost	18,504	22,705
Income from grants	(607,264)	(2,213,799)
Advanced depreciation deduction	—	1,966,398
Loss(profit) on sales of stocks of subsidiary	(7,473)	—
Decrease(increase) in Account receivable	108,225	(14,502)
Increase(decrease) deposit receivable	(2,475)	10,241
Other	(544,933)	336,909
Subtotal	(3,457,263)	(1,738,866)
Interest and dividends received	945	541
Interest paid	(227,539)	(166,870)
Grants received	204,264	2,316,799
Income taxes paid	(29,718)	(6,077)
Other	(69,147)	(90,861)
Net cash provided by (used in) operating activities	(3,578,459)	314,665
Net cash provided by (used in) investing activities		
Purchase of tangible fixed assets	(3,894,139)	(5,004)
Purchase of intangible fixed assets	(425,671)	(3,306)
Purchase of guarantee deposits	—	(600)
Proceeds from collection of guarantee deposits	240	—
Purchase of Lease deposits	(18,292)	(145)
Proceeds from collection of lease deposits	11,985	336
Proceeds from sales of securities	167,817	—
Proceeds from sales of investments in subsidiary	7,500	—
Purchase of long-term prepaid expenses	(60)	—
Net cash provided by (used in) investing activities	(4,150,619)	(8,719)
Net cash provided by (used in) financing activities		
Proceeds from short-term loan	3,386,400	2,470,000
Repayment for purchase of short-term loan	(1,950,000)	(3,384,300)
Proceeds from Long-term loan	3,025,000	—
Repayment for purchase of long-term loan	(350,000)	(4,920,000)
Proceeds from issuance of common stock	3,599,274	3,441,659
Proceeds from issuance of common stock from minority	494,000	—
Repayment for purchase of lease obligations	(90,684)	(94,490)
Other	(197)	(6,251)
Net cash provided by (used in) financing activities	8,113,793	(2,493,382)
Net increase(decrease) in cash and cash equivalents	384,714	(2,187,436)
Cash and cash equivalent at beginning of the period	3,882,943	4,267,657
Cash and cash equivalent at end of the period	4,267,657	2,080,221